Form 4 · Filed Jun 5, 2026, 08:29 PM UTC
ABOS/Acumen Pharmaceuticals, Inc.
Ives Jeffrey L. — director
AI Thesis
A thesis has not been generated for this filing yet — usually available within 60 seconds of EDGAR publication. Refresh shortly.
Research signal, not investment advice. Form 4 AI surfaces SEC filings and applies an analytical layer — it does not predict prices or recommend trades. Past performance does not guarantee future results. See methodology and public track record for how scores are computed.
Transactions
2 rows| Date | Code | Direction | Shares | Price | Value | Owned after |
|---|---|---|---|---|---|---|
| Jun 3, 2026 | A | other | 35,500 | $0 | — | 48,300 |
| Jun 3, 2026 | A | other | 53,250 | — | — | 53,250 |
Source: SEC EDGAR raw filing ↗ · Accession 0001628280-26-041270